-+ 0.00%
-+ 0.00%
-+ 0.00%

Radiopharm Theranostics Announces Updated Clinical Results From First Two Patients In Third Cohort Of RAD204; First RECIST-Confirmed Durable Partial Response At Current Highest Dose Level #3, With Patient Progression Free Beyond Seven Months

Benzinga·07/22/2026 11:10:58
Listen to the news

Second patient dosed remains progression free on treatment with RAD204 with early tumor shrinkage observed after first treatment

RAD204 is generally well-tolerated with no dose-limiting toxicities observed in any of the dosing cohorts thus far